Apnimed Files for $100 Million IPO With Sleep Apnea Pill Awaiting FDA Decision

One Drug, One Shot at the Public Markets

Apnimed filed its IPO paperwork with the SEC on Friday, July 10, seeking to raise up to $100 million, according to Renaissance Capital. The Cambridge, Massachusetts company, founded in 2017, plans to list on Nasdaq under the ticker symbol APMD.

The company has exactly one clinical candidate: AD109, now branded Oxnimbi. According to Renaissance Capital, it is a fixed-dose neuromuscular modulator that combines an anti-muscarinic agent with a selective norepinephrine reuptake inhibitor. The mechanism is designed to improve upper airway muscle activity and stop the airway from collapsing during sleep, the core problem in obstructive sleep apnea (OSA).

Oxnimbi is taken once daily at bedtime. That matters because the current standard of care for OSA is a CPAP machine, a device that keeps airways open by pumping pressurized air through a mask worn overnight. Compliance with CPAP is notoriously poor. A pill is a fundamentally easier ask.

Where the Drug Stands

Apnimed studied Oxnimbi in 1,300 patients across multiple Phase 3 trials, according to Renaissance Capital. In May 2026, the drug met its primary endpoint in a late-stage trial, per Reuters. The company submitted a New Drug Application (NDA) to the FDA in April 2026, and Reuters reports that Apnimed expects a potential FDA decision in the first quarter of 2027.

No FDA decision has been issued as of today, July 10, 2026. That is the single largest variable hanging over this offering.

The Numbers Behind the Filing

Apnimed booked $120 million in revenue for the 12 months ended March 31, 2026, according to Renaissance Capital. For a clinical-stage company still awaiting its first approval, that figure is notable and warrants scrutiny. It likely reflects milestone payments, grants, or collaboration revenue rather than commercial product sales, though the sources do not specify the breakdown.

The $100 million IPO target is the placeholder figure in the filing. Final pricing terms have NOT been disclosed, per Renaissance Capital.

BofA Securities, Evercore ISI, Cantor Fitzgerald, and LifeSci Capital are the underwriters on the deal, according to Reuters.

Apnimed filed confidentially with the SEC on July 1, 2024, according to Renaissance Capital, meaning the company has been watching market conditions for two years before pulling the trigger publicly.

Why Now

Biotech IPOs collapsed in 2024 and 2025. Reuters reports that public offerings in the sector fell to their lowest level in more than a decade in 2025. The market has been recovering in 2026 as capital returns to the sector.

Apnimed is timing this IPO with its NDA already under FDA review. Companies with approved drugs command better valuations than those still in trials, and filing while the NDA is live but before a decision captures some of that upside while leaving room for a post-approval jump if Oxnimbi gets the green light.

The Single-Asset Bet

The strongest bear case is straightforward: Apnimed has one drug. If the FDA issues a Complete Response Letter, rejecting or delaying Oxnimbi, the company has nothing else in the pipeline to fall back on, at least based on what is publicly disclosed. Single-asset biotechs live and die on one regulatory decision.

That concern is not hypothetical. FDA review timelines slip. Phase 3 success does not guarantee approval. The agency has requested additional data or raised labeling concerns for drugs that cleared late-stage trials before. Investors buying into this IPO before a Q1 2027 FDA decision are placing a significant regulatory bet.

The counter-argument: Apnimed's Phase 3 data package appears robust. 1,300 patients across multiple trials is a meaningful evidence base, and an NDA acceptance means the FDA found the filing complete enough to review. The company also has experienced underwriters and an already-submitted NDA, not a speculative pipeline.

What Obstructive Sleep Apnea Actually Represents

OSA is not a niche market. It is one of the most underdiagnosed chronic conditions in the country. Millions of Americans have it and either don't know or refuse to use CPAP. An effective oral therapy for OSA would be a significant commercial opportunity, which is exactly why this IPO is attracting four underwriting banks and considerable attention despite the single-asset risk.

Valuation Ahead

Apnimed still needs to set a price per share and an IPO date. The unresolved question for investors: what valuation will the market assign to a company with $120 million in pre-commercial revenue, one drug under FDA review, and a potential approval decision six to nine months away? The answer will determine whether this IPO is a biotech recovery story or a cautionary tale about timing.